HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Urtė Fultinavičiūtė

Reporter

London, UK

Urtė has previously worked as a Healthcare Reporter at GlobalData Media, primarily writing for Clinical Trials Arena. She mostly focused on clinical trial data management, strategy, and regulatory updates as well as clinical trial data readouts and exclusive interviews with C-level pharma and biotech executives. Urtė holds an MA in International Journalism from City, University of London.

Latest From Urtė Fultinavičiūtė

Gedeon Richter’s Q1 Hit By Weak Ruble But Expects More M&A In Q2

With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.

Deals Strategy

Gedeon Richter Teases Denosumab Partnering Opportunity In Japan

While investigating the potential of the Japanese market for its denosumab, Gedeon Richter is preparing for several regulatory filings, including its tocilizumab biosimilar.

Biosimilars Deals

MS Pharma Bags Formycon’s Eylea Biosimilar Rights In MENA

With an already established network, Formycon’s aflibercept biosimilar licensee Klinge follows in the same footsteps by picking MS Pharma as its MENA region partner.

Biosimilars Deals

Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds

As different US authorities keep pointing fingers at each other over who is responsible for improper patent listings, a study looks at patent applications that are filed after an FDA approval.

United States Market Access

AAM Applauds CMS For Biosimilar Substitution Flexibility In Medicare Part D Plans

Despite receiving mixed opinions on the Medicare Part D final rule, CMS sees support from the off-patent group AAM, which said that the new policy will have an “immediate impact” on cost reduction and increased access to biosimilars.

Biosimilars Medicare

Celltrion Offers 85% Discount For Adalimumab Biosimilar In US

Celltrion joins a number of other adalimumab competitors with dual pricing strategies as Humira biosimilars finally gain some traction in the US market.

United States Biosimilars
See All
UsernamePublicRestriction

Register